1227210-31-2

Basic information

• Product Name: 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole
• CAS NO: 1227210-31-2
• Molecular Formula: C₆H₇Br₂N₃O₂
• Molecular Weight: 312.94848
• Mol File: 1227210-31-2.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole(1227210-31-2)
• EPA Substance Registry System: 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole(1227210-31-2)

Safety Data

• Hazardous Substances Data: 1227210-31-2(Hazardous Substances Data)

Usage

Chemical structure

A pyrazole derivative with two bromine atoms and a nitro group attached to the pyrazole ring

Applications

a. Organic synthesis
b. Pharmaceutical research
c. Building block for the preparation of various biologically active molecules
d. Synthesis of advanced materials, fine chemicals, and pharmaceuticals
e. Medicinal chemistry and agrochemicals due to unique biological activities
f. Starting material for the synthesis of new pyrazole derivatives with potential therapeutic properties

Structural features

Valuable intermediate for the synthesis of various compounds

Potential

Wide range of applications in different fields due to its unique properties and reactivity

Upstream product

• 106-93-4 ethylene dibromide 
• 181585-93-3 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester 
• 1360057-00-6 methyl 1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-carboxylate 
• 1227210-30-1 (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol 

Downstream Products

• 1227210-32-3 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 1209487-56-8 tert-butyl 2-amino-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate 
• 1433854-27-3 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(5-(2,2,2-trifluoro-ethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one 
• 1333508-99-8 1-(2-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethanone 
• 1333508-96-5 2-nitro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine 
• 1346673-34-4 5-cyclopropyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 1227210-33-4 5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl-amine 

Relevant articles and documents

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.